BACKGROUND: Heart failure (HF) is a major chronic illness and results in high morbidity and mortality. The most frequent cause of HF with reduced ejection fraction (HFREF) is coronary artery disease (CAD). Although revascularisation of ischemic myocardium lead to improvements in myocardial contractility and systolic function, it cannnot restore the viability of the already necrotic myocardium. METHODS/DESIGN: The aim of our prospective randomised study is to assess the efficacy of the retrograde application of non-selected bone marrow autologous cells concentrate (BMAC) in patients with HFREF of ischemic aetiology. The evaluated preparation is concentrated BMAC, obtained using Harvest SmartPReP2 (Harvest Technologies, Plymouth, MA, USA). The study population will be a total of 40 patients with established CAD, systolic dysfunction with LV EF of ≤40% and HF in the NYHA class 3. Patients have been on standard HF therapy for 3 months and in a stabilised state for at least 1 month, before enrolling in the clinical study. Patients will be randomised 1:1 to either retrograde BMAC administration via coronary sinus or standard HF therapy. The primary end-points (left ventricular end-systolic and end-diastolic diameters [LVESd/EDd] and volumes [LVESV/EDV] and left ventricular ejection fraction [LV EF]) will be assessed by magnetic resonance imaging. The follow-up period will be 12 month. DISCUSSION: The application of bone marrow stem cells into affected areas of the myocardium seems to be a promising treatment of ischemic cardiomyopathy. The Harvest BMAC contains the entire population of nuclear cells from bone marrow aspirates together with platelets. The presence of both platelets and additional granulocytes can have a positive effect on the neovascularisation potential of the resulting concentrate. Our assumption is that retrograde administration on non-selected BMAC via coronary sinus, due to the content of platelets and growth factors, might improve left ventricular function and parameters compared to standard HF therapy. Furthermore, it will be associated with improved exercise tolerance in the six-minute corridor walk test and an improvement in the life quality of patients without increasing the incidence of severe ventricular arrythmias. TRIAL REGISTRATION: (ClinicalTrials.gov; https://clinicaltrials.gov ; NCT03372954).

Department of Cardiovascular Diseases University Hospital Ostrava tr 17 listopadu 1790 708 52 Ostrava 8 Czech Republic

Department of Science and Research University Hospital Ostrava Ostrava Czech Republic

RDG Institute University Hospital Ostrava Ostrava Czech Republic

Zobrazit více v PubMed

Jeevanantham V, Butler M, Saad A, Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters a systematic review and meta-analysis. Circulation. 2012;126:551–568. doi: 10.1161/CIRCULATIONAHA.111.086074. PubMed DOI PMC

van der Spoel TIG, Lorkeers SJ, Agostoni P, van Belle E, Gyongyosi M, Sluijter JPG, et al. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res. 2011;91:649–658. doi: 10.1093/cvr/cvr113. PubMed DOI

Wu KH, Hanb ZC, Moa XM, Zhou B. Cell delivery in cardiac regenerative therapy. Ageing Res Rev. 2012;11:32–40. doi: 10.1016/j.arr.2011.06.002. PubMed DOI

Patel AN, Mittal S, Turan G, Winters AA, Henry TH, Ince H, et al. REVIVE trial: retrograde delivery of autologous bone marrow in patients with heart failure. Stem Cells Transl Med. 2015;4:1021–1027. doi: 10.5966/sctm.2015-0070. PubMed DOI PMC

Kwon DH, Asamoto L, Popovic ZB, Kusunose K, Robinson M, Desai M, et al. Infarct characterization and quantifcation by delayed enhancement cardiac magnetic resonance imaging is a powerful independent and incremental predictor of mortality in patients with advanced ischemic cardiomyopathy. Circ Cardiovasc Imaging. 2014;7:796–804. doi: 10.1161/CIRCIMAGING.114.002077. PubMed DOI

Mathiasen AB, Qayyum AA, Jørgensen E, Helqvist S, Fischer-Nielsen A, Kofoed KF, et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial) Eur Heart J. 2015;36:1744–1753. doi: 10.1093/eurheartj/ehv136. PubMed DOI

Lerman DA, Alotti N, Ume KL, Péault B. Cardiac Repair And Regeneration: The Value Of Cell Therapies. Eur Cardiol Rev. 2016;11(1):43–48. doi: 10.15420/ecr.2016:8:1. PubMed DOI PMC

Katarzyna R. Adult stem cell therapy for cardiac repair in patients after acute myocardial infarction leading to ischemic heart failure: an overview of evidence from the recent clinical trials. Curr Cardiol Rev. 2017;13(3):223–231. doi: 10.2174/1573403X13666170502103833. PubMed DOI PMC

Takashima S, Tempel D, Duckers HJ. Current outlook of cardiac stem cell therapy towards a clinical application. Heart 2013;0:1–13. doi:10.1136/heartjnl-2012-303308. PubMed

Sheng CC, Zhou L, Hao J. Current Stem Cell Delivery Methods for Myocardial Repair. BioMed Res Int. 2013; Article ID 547902: 1–15. 10.1155/2013/547902 PubMed PMC

Strauer BE, Steinhoff G. 10 Years of Intracoronary and Intramyocardial Bone Marrow Stem Cell Therapy of the Heart From the Methodological Origin to Clinical Practice. JACC. 2011;58(11):1095–1104. doi: 10.1016/j.jacc.2011.06.016. PubMed DOI

Delewi R, Andriessen A, Tijssen JGP, Schächinger V, Wojakowski W, Roncalli J, et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a meta-analysis of randomised controlled clinical trials. Heart. 2013;99:225–232. doi: 10.1136/heartjnl-2012-302230. PubMed DOI

Gyöngyösi M, Giurgea GA, Syeda B, Charwat S, Marzluf B, Mascherbauer J, et al. Long-term outcome of combined (Percutaneous intramyocardial and intracoronary) application of autologous bone marrow mononuclear cells post myocardial infarction: the 5-year MYSTAR study. PLoS One. 2016;11(10):e0164908. doi: 10.1371/journal.pone.0164908. PubMed DOI PMC

Wu K, Mo X, Lu S, Han Z. Retrograde delivery of stem cells: promising delivery strategy for myocardial regenerative therapy. Clin Transpl. 2011;25:830–833. doi: 10.1111/j.1399-0012.2011.01508.x. PubMed DOI

Gathier WA, van Ginkel DJ, van der Naald M, van Slochteren FJ, Doevendans PA, Chamuleau SAJ. Retrograde coronary venous infusion as a delivery strategy in regenerative cardiac therapy: an overview of preclinical and clinical data. J Cardiovasc Transl Res. 2018;11:173–181. doi: 10.1007/s12265-018-9785-1. PubMed DOI PMC

Suzuki K, Murtuza B, Fukushima S, Smolenski RT, Varela-Carver A, Coppen SR, et al. Targeted cell delivery into infarcted rat hearts by retrograde intracoronary infusion: distribution, dynamics, and influence on cardiac function. Circulation. 2004;110(11):II225–II230. doi: 10.1161/01.CIR.0000141295.60857.30. PubMed DOI

Zhou R, Acton PD, Victor A, Ferrari VA. Imaging stem cells implanted in infarcted myocardium. J Am Coll Cardiol. 2006;48:2094–2106. doi: 10.1016/j.jacc.2006.08.026. PubMed DOI PMC

Silva SA, Sousa ALS, Haddad AF, Azevedo JC, Soares VE, Peixoto CM, et al. Autologous bone-marrow mononuclear cell transplantation after acute myocardial infarction: comparison of two delivery techniques. Cell Transplant. 2009;18:343–352. doi: 10.3727/096368909788534951. PubMed DOI

Vicario J, Campos C, Piva J, Faccio F, Gerardo L, Becker C, et al. Transcoronary sinus administration of autologous bone marrow in patients with chronic refractory stable angina phase 1. Cardiovasc Radiat Med. 2004;5:71–76. PubMed

Ortega H, Pierini A, Lofeudo C, Novero R, Balino NP, Monti A, et al. One-year follow-up of transcoronary sinus administration of autologous bone marrow in patients with chronic refractory angina. Cardiovasc Revasc Med. 2005;6:99–107. doi: 10.1016/j.carrev.2005.08.002. PubMed DOI

Tuma J, Carrasco A, Castillo J, Cruz C, Carrillo A, Ercilla J, et al. RESCUE-HF trial: retrograde delivery of allogeneic umbilical cord lining subepithelial cells in patients with heart failure. Cell Transplant. 2016;25:1713–1721. doi: 10.3727/096368915X690314. PubMed DOI

Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311(1):62–73. doi: 10.1001/jama.2013.282909. PubMed DOI PMC

Tuma J, Fernández-Viña R, Carrasco A, Castillo J, Cruz C, Carrillo A, et al. Safety and feasibility of percutaneous retrograde coronary sinus delivery of autologous bone marrow mononuclear cell transplantation in patients with chronic refractory angina. J Transl Med. 2011;9:183. doi: 10.1186/1479-5876-9-183. PubMed DOI PMC

Afzal MR, Samanta A, Shah ZI, Jeevanantham V, Abdel-Latif A, et al. Adult bone marrow cell therapy for ischemic heart disease evidence and insights from randomized controlled trials. Circ Res. 2015;117:558–575. doi: 10.1161/CIRCRESAHA.114.304792. PubMed DOI PMC

Shahid MSS, Lasheen W, Haider KH. The modest outcome of clinical trials with bone marrow cells for myocardial repair: is the autologous source of cells the prime culprit? J Thorac Dis. 2016;8(10):E1371–E1374. doi: 10.21037/jtd.2016.10.37. PubMed DOI PMC

Haider KH. Bone marrow cell therapy and cardiac reparability: better cell characterization will enhance clinical success. Regen Med. 2018;13(4):457–475. doi: 10.2217/rme-2017-0134. PubMed DOI

Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 2003;33:919–926. doi: 10.1016/j.bone.2003.07.005. PubMed DOI

Zhou S, Greenberger JS, Epperly MW, Goff JP, Adler C, Leboff MS, et al. Age-related intrinsic changes in human bone marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell. 2008;7(3):335–343. doi: 10.1111/j.1474-9726.2008.00377.x. PubMed DOI PMC

Hermann PC, Huber SL, Herrler T, von Hesler C, Andrassy J, Kevy SV, et al. Concentration of bone marrow total nucleated cells by a point-of-care device provides a high yield and preserves their functional activity. Cell Transplant. 2008;16(10):1059–1069. doi: 10.3727/000000007783472363. PubMed DOI

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Europ Heart J. 2016;37:2129–2200. doi: 10.1093/eurheartj/ehw128. PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03372954